Where do CRISPR Therapeutics's ratios come from?

Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	-15,754.2%+3,179pp	-18,933.6%-17,435pp	-1,498.3%—	——	——
Net margin	-13,856.5%+2,713pp	-16,569.8%-15,296pp	-1,273.7%—	——	——
EBITDA margin	-15,289.6%+3,089pp	-18,378.7%-16,929pp	-1,449.6%—	——	——
Free cash flow margin	-9,777.6%+77.9pp	-9,855.5%-9,065pp	-790.7%+64.9pp	-855.6%-38.5pp	-817.1%-429pp
Returns
Return on equity	-31.2%-1.0pp	-30.2%-4.9pp	-25.3%—	——	——
Return on assets	-23.2%+2.6pp	-25.8%-4.1pp	-21.7%—	——	——
Return on invested capital	-32.4%+4.1pp	-36.5%-6.2pp	-30.4%—	——	——
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	18×+4.6×	13.3×-2.9×	16.2×-0.4×	16.6×+1.0×	15.6×-6.4×
Quick ratio	18×+4.6×	13.3×-2.9×	16.2×-0.4×	16.6×+1.0×	15.6×-6.4×
Cash ratio	3.1×+0.8×	2.3×-0.1×	2.4×+0.6×	1.9×-0.1×	2×-1.4×
Leverage
Debt-to-equity	0.4×+0.3×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.3×+0.2×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Per Share
Book value per share	$18.89-11.6%	$21.37+1.8%	$20.98+6.8%	$19.65-7.7%	$21.28-7.1%
Valuation
Market capitalization	$4.57B-8.6%	$5B-15.2%	$5.89B+45.9%	$4.04B+38.4%	$2.92B-13.1%
Enterprise value	$4.93B+1.5%	$4.86B-16.5%	$5.82B+43.3%	$4.06B+39.9%	$2.9B-11.6%
Price / sales	1,112.8×-311×	1,423.8×+1,270×	153.8×+47.6×	106.2×+28.7×	77.5×-12.6×
Price / book	2.5×-0.1×	2.6×-0.5×	3.1×+0.7×	2.4×+0.8×	1.6×-0.1×
EV / sales	1,201.6×-182×	1,383.7×+1,232×	151.8×+45.0×	106.8×+29.7×	77.1×-11.0×
Free cash flow yield	-8.8%-1.9pp	-6.9%-1.8pp	-5.1%+2.9pp	-8.1%+2.5pp	-10.5%-6.2pp
Earnings yield	-12.5%-0.8pp	-11.6%-3.4pp	-8.3%—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do CRISPR Therapeutics's ratios come from?: Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.